Zacks: Analysts Anticipate Mersana Therapeutics Inc (NASDAQ:MRSN) Will Post Quarterly Sales of $500,000.00
Equities analysts expect Mersana Therapeutics Inc (NASDAQ:MRSN) to announce $500,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from $250,000.00 to $1.00 million. Mersana Therapeutics posted sales of $1.19 million in the same quarter last year, which would indicate a negative year over year growth rate of 58%. The firm is expected to report its next quarterly earnings results on Friday, March 13th.
On average, analysts expect that Mersana Therapeutics will report full year sales of $42.38 million for the current fiscal year, with estimates ranging from $42.08 million to $43.10 million. For the next year, analysts anticipate that the firm will report sales of $1.50 million, with estimates ranging from $1.00 million to $2.50 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02. The business had revenue of $0.84 million for the quarter, compared to the consensus estimate of $0.50 million. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%.
A number of institutional investors and hedge funds have recently bought and sold shares of MRSN. Boxer Capital LLC acquired a new stake in Mersana Therapeutics during the second quarter worth $8,440,000. BlackRock Inc. boosted its stake in Mersana Therapeutics by 166.2% during the second quarter. BlackRock Inc. now owns 2,390,463 shares of the company’s stock worth $9,681,000 after buying an additional 1,492,618 shares in the last quarter. Vanguard Group Inc. boosted its stake in Mersana Therapeutics by 26.9% during the second quarter. Vanguard Group Inc. now owns 1,903,502 shares of the company’s stock worth $7,709,000 after buying an additional 403,011 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Mersana Therapeutics during the second quarter worth $676,000. Finally, Millennium Management LLC boosted its stake in Mersana Therapeutics by 136.0% during the third quarter. Millennium Management LLC now owns 42,524 shares of the company’s stock worth $67,000 after buying an additional 160,624 shares in the last quarter. Hedge funds and other institutional investors own 80.37% of the company’s stock.
Shares of Mersana Therapeutics stock traded up $0.25 during midday trading on Friday, hitting $7.92. The company had a trading volume of 339,800 shares, compared to its average volume of 644,700. The business’s 50 day simple moving average is $5.41 and its two-hundred day simple moving average is $3.31. The stock has a market cap of $367.24 million, a PE ratio of -8.08 and a beta of 2.35. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.12 and a quick ratio of 5.12. Mersana Therapeutics has a 1-year low of $1.32 and a 1-year high of $8.93.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Recommended Story: Closed-End Mutual Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.